interleukin 1 receptor antagonist
| GO Term | Evidence Code | PMID |
|---|---|---|
| fever generation | ||
| lipid metabolic process | ||
| acute-phase response | ||
| inflammatory response | ||
| inflammatory response |
| GO Term | Evidence Code | PMID |
|---|---|---|
| extracellular region | ||
| extracellular space | ||
| extracellular space | ||
| extracellular space | ||
| nucleoplasm |
| GO Term | Evidence Code | PMID |
|---|---|---|
| cytokine activity | ||
| interleukin-1 receptor binding | ||
| interleukin-1, type I receptor binding | ||
| interleukin-1, type I receptor binding | ||
| interleukin-1, type II receptor binding |
| Gene Ontology |
|---|
| cellular response to lipopolysaccharide |
| cytokine activity |
| immune response |
| inflammatory response to antigenic stimulus |
| inflammatory response |
| interleukin-1 receptor binding |
| InterPro |
|---|
| Cytokine IL1/FGF |
| Interleukin-1 family |
| Interleukin-1 receptor antagonist/Interleukin-36 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025